Business
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
The SAV technology has been exclusively licensed from Massachusetts General Hospital Preclinical development to be undertaken in conjunction with Voltron
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The SAV technology has been exclusively licensed from Massachusetts General Hospital\n Preclinical development to be undertaken in conjunction with Voltron Therapeutics and the Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital\n\n\nNEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be named HaloVax) to commence preclinical studies for the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). \n\n \n \n \n \n \n \n\n \nHoth and Voltron, with the support of MGH, will work jointly on exploring and developing this SAV technology as a means to aid patients at risk of being infected with COVID-19. [The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology which received Department of Defense (DoD) funding has demonstrated proof of concept in Lassa Fever, an emerging infectious disease. HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic.\nHoth believes VaxCelerate offers two unique elements to combat the Coronavirus - one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.\nVaxCelerate was founded by Dr. Mark Poznansky, MD, PhD, and Dr. Jeffrey Gelfand, MD, who will both continue to support its research and development. Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and a Physician at Massachusetts General Hospital, as well as an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member of Halova...